ArticleFrontiers in endocrinology2026
Quantitative assessment of active charcot neuro-osteoarthropathy in diabetes using
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: No single imaging modality currently provides quantitative assessment of disease activity in active charcot neuro-osteoarthropathy (CNO) of the foot, either at diagnosis or during follow-up after clinical remission. This study evaluates the role of Methods: In this prospective study, 80 patients with diabetes presenting with asymmetric foot swelling were screened and assessed using an infrared thermometer. 39 symptomatic patients were included (33 active CNO and 6 non-CNO) and underwent magnetic resonance imaging (MRI) and Results: Median SUVmax (baseline) was 55.1 in active CNO versus 7.5 in non-CNO (p<0.001). An SUVmax value of ≥10.3 yielded 100% sensitivity (95% CI 89.4-100%) and 92.3% specificity (95% CI 74.9-99.1%) against all controls (AUC 0.988, 95% CI 0.965-1.000); specificity was 66.7% against symptomatic non-CNO patients. 29 participants achieved clinical remission, and SUVmax decreased from 58.3 to 19.6 (61.9% reduction; p<0.001). 4 patients with active CNO relapse showed significantly lower SUVmax reduction than those with sustained remission (28.4% vs 64.7%, p=0.006). In exploratory analysis, greater reduction in SUVmax between baseline and clinical remission was associated with lower recurrence risk (HR 0.970 per 1% greater reduction, 95% CI 0.941-0.999). With only four events, this finding is hypothesis-generating. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.